Background Despite the goal set by WHO to eliminate hepatitis C virus (HCV) as a public
health threat, uptake of HCV testing and treatment remains low. To achieve this target …

Background There are concerns around poorer response to direct-acting antiviral (DAA)
therapy for hepatitis C virus infection among people who use drugs. This systematic review …

Abstract Background and Aims People who have recently injected drugs are a priority
population in efforts to achieve hepatitis C virus (HCV) elimination. This study estimated the …

Background Increasing access to hepatitis C virus (HCV) care and treatment will require
simplified service delivery models. We aimed to evaluate the effects of decentralisation and …

Viral hepatitis is a major public health threat and a leading cause of death worldwide.
Annual mortality from viral hepatitis is similar to that of other major infectious diseases such …

Introduction The COVID-19 pandemic has disrupted healthcare services, reducing
opportunities to conduct routine hepatitis C virus antibody screening, clinical care, and …

Direct-acting antivirals (DAAs) for hepatitis C virus (HCV) infection have delivered high
response rates (> 95%) and simplified the management of HCV treatment, permitting non …

Introduction: Globally, there is a considerable burden of HCV and HIV infections among
people who inject drugs (PWID) and transmission of both infections continues. Needle and …

Introduction: The availability of simple, tolerable, therapies for hepatitis C virus (HCV)
infection with responses> 95% is one of the greatest medical advances in decades, offering …

Background With the advent of direct acting antiviral (DAA) therapies for the treatment of
hepatitis C virus (HCV), the World Health Organization recommended a goal to eliminate …